Ahmad A Tarhini

Dec 9, 2024 | cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi

Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma Panelists discuss how dual immunotherapy for melanoma, including combinations like nivolumab plus ipilimumab or nivolumab plus relatlimab, requires careful consideration of sequencing decisions based on factors such as tumor burden, patient health status, and potential toxicity profiles.

Dec 9, 2024 | cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi

Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067Panelists discuss how the indirect treatment comparison of RELATIVITY-047 and CheckMate 067 suggests that nivolumab plus relatlimab may provide similar efficacy to nivolumab plus ipilimumab in advanced melanoma, with a potentially better safety profile.

Dec 2, 2024 | cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi

2 Commerce Drive Cranbury, NJ 08512

Dec 2, 2024 | cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi

Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced MelanomaPanelists discuss how the RELATIVITY-047 trial data highlights the efficacy of nivolumab plus relatlimab in managing advanced melanoma, offering improved progression-free survival with a favorable safety profile compared to with nivolumab alone.

Aug 19, 2024 | onclive.com | Ahmad A Tarhini

CommentaryVideoAugust 19, 2024Author(s):Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.